Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma.
Megumi Goto,Kenji Chamoto,Keiko Higuchi,Saya Yamashita,Kenta Noda,Iino Takuya,Masahiro Miura,Toshinari Yamasaki,Osamu Ogawa,Makoto Sonobe,Hiroshi Date,Junzo Hamanishi,Masaki Mandai,Yoshimasa Tanaka,Shunsuke Chikuma,Ryusuke Hatae,Manabu Muto,Sachiko Minamiguchi,Nagahiro Minato,Tasuku Honjo +19 more
Reads0
Chats0
TLDR
Application of this rapid and sensitive immunoassay system to plasma of patients with several types of tumours demonstrated that soluble PD-1, PD-L1, and CTLA-4 levels were increased compared to those of healthy controls and varied among tumour types.Abstract:
Current clinically approved biomarkers for the PD-1 blockade cancer immunotherapy are based entirely on the properties of tumour cells. With increasing awareness of clinical responses, more precise biomarkers for the efficacy are required based on immune properties. In particular, expression levels of immune checkpoint-associated molecules such as PD-1, PD-L1, and CTLA-4 would be critical to evaluate the immune state of individuals. Although quantification of their soluble form leased from the membrane will provide quick evaluation of patients' immune status, available methods such as enzyme-linked immunosorbent assays to measure these soluble factors have limitations in sensitivity and reproducibility for clinical use. To overcome these problems, we developed a rapid and sensitive immunoassay system based on chemiluminescent magnetic technology. The system is fully automated, providing high reproducibility. Application of this system to plasma of patients with several types of tumours demonstrated that soluble PD-1, PD-L1, and CTLA-4 levels were increased compared to those of healthy controls and varied among tumour types. The sensitivity and detection range were sufficient for evaluating plasma concentrations before and after the surgical ablation of cancers. Therefore, our newly developed system shows potential for accurate detection of soluble PD-1, PD-L1, and CTLA-4 levels in the clinical practice.read more
Citations
More filters
Journal ArticleDOI
The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy.
Linda Quatrini,Francesca Romana Mariotti,Enrico Munari,Nicola Tumino,Paola Vacca,Lorenzo Moretta +5 more
TL;DR: Further insight is provided into the expression and function of the immune checkpoint PD-1 in natural killer cells, together with the limitations and perspectives of immunotherapies aimed at blocking the interaction of this inhibitory receptor with its ligands.
Journal ArticleDOI
Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: a pilot study
TL;DR: It is shown that PD-L1 is highly expressed in premalignant lesions progressing to cancer, suggesting that immunomodulation via PD- L1/PD-1 pathway occurs prior to malignant transformation.
Journal ArticleDOI
Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases.
TL;DR: In this article, the authors reviewed the different origins and roles of sPD-L1 in humans to highlight the biochemical and functional heterogeneity of the soluble protein, and the structural heterogeneity of s PD-L 1 proteins should be kept in mind when considering sPDL1 as a biomarker or as a drug target.
Journal ArticleDOI
Self‐Blockade of PD‐L1 with Bacteria‐Derived Outer‐Membrane Vesicle for Enhanced Cancer Immunotherapy
TL;DR: In this article , an LyP1 polypeptide-modified outer-membrane vesicle (LOMV) loaded with a PD-1 plasmid is developed to achieve self-blockade of PD-L1 in tumor cells.
Journal ArticleDOI
Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients
Yusuke Omura,Yuji Toiyama,Yoshinaga Okugawa,Chengzeng Yin,Tsunehiko Shigemori,Kurando Kusunoki,Yukina Kusunoki,Shozo Ide,Tadanobu Shimura,Hiroyuki Fujikawa,Hiromi Yasuda,Junichiro Hiro,Masaki Ohi,Masato Kusunoki +13 more
TL;DR: Dual evaluation of immune checkpoint molecules in primary tissues or preoperative serum could identify a patient population with poor prognosis in these patients.
References
More filters
Journal ArticleDOI
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck,Delvys Rodriguez-Abreu,Andrew G. Robinson,Rina Hui,Tibor Csőszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Suman Rao,Katsuyuki Hotta,Melanie A. Leiby,Gregory M. Lubiniecki,Yue Shentu,Reshma A. Rangwala,Julie R. Brahmer +17 more
TL;DR: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express PD-L1 as mentioned in this paper.
Journal ArticleDOI
Enhancement of antitumor immunity by CTLA-4 blockade.
TL;DR: In vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors, and this rejection resulted in immunity to a secondary exposure to tumor cells, suggesting that blockade of the inhibitory effects of CTLA4 can allow for, and potentiate, effective immune responses against tumor cells.
Journal ArticleDOI
Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
TL;DR: The results suggest that activation of the PD‐1 gene may be involved in the classical type of programmed cell death.
Journal ArticleDOI
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
TL;DR: It is suggested that PD-1 is involved in the maintenance of peripheral self-tolerance by serving as a negative regulator of immune responses in lymphocytes and monocytic cells following activation.
Journal ArticleDOI
The b7 family revisited
TL;DR: The roles of the B7:CD28 family members in regulating immune responses are revisited, and the therapeutic potential of these families is discussed.
Related Papers (5)
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response.
Laurence P. Diggs,Eddy C. Hsueh +1 more
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future.
Hyojin Kim,Jin Haeng Chung +1 more